Viking Therapeutics, Inc. VKTX
Set alert
At close · Nov 2
After hours · Nov 2, 6:37 PM ET
- YTD
- -23.74%
- 1 year
- -29.54%
- Open
- 27.25
- Prev close
- 27.28
- Mkt cap
- 3.42B
- Vol
- 4.43M
- Avg vol
- 4.79M
- EPS
- -5.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 26.54
- High
- 27.89
- Forward P/E
- -5.28
- Beta
- 0.75
- Short ratio
- 2.88
- Inst. own
- 60.24%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 10, 2027
- 50-d avg
- 30.51
- 200-d avg
- 32.40
- 1y target
- 95.32
5D chart
Events in this range
- Oct 28, 2026Earnings: -1.55; estimate -1.06; surprise -46.23%
- Oct 30, 2026Rating: Canaccord Genuity · Buy → Buy
Signals (110)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:55 PM | 9 hours ago |
| MACD: Buy Signal | Nov 2, 3:50 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 3:45 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 3:45 PM | 9 hours ago |
| MACD: Sell Signal | Nov 2, 3:25 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 3:20 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 3:15 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 3:10 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 2:55 PM | 10 hours ago |
| MACD: Buy Signal | Nov 2, 2:55 PM | 10 hours ago |
| SMA: Bearish | Nov 2, 2:45 PM | 10 hours ago |
| SMA: Bullish | Nov 2, 2:40 PM | 10 hours ago |
| MACD: Sell Signal | Nov 2, 1:50 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 1:35 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 1:30 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 1:25 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 12:55 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 12:35 PM | 12 hours ago |
| MACD: Buy Signal | Nov 2, 12:30 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 12:20 PM | 12 hours ago |
Newest 20 of 110.
News
17 hours ago fool.com
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
UBS sees approximately 250% upside potential for Viking shares over the next year. Viking's weight loss candidates could compete effectively with the established drugs from Eli Lilly and Novo Nordisk.
-
3 days ago benzinga.com
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118
Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $106 to $118.
3 days ago zacks.com
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.
3 days ago zacks.com
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often…
4 days ago seekingalpha.com
Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)
Viking Therapeutics, Inc. is advancing VK2735, a dual GLP-1/GIP agonist, targeting the obesity and diabetes market dominated by Eli Lilly and Novo Nordisk. VKTX's Phase 3 VANQUISH trials for…
4 days ago zacks.com
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.
4 days ago zacks.com
VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress
Viking Therapeutics advances its Phase III obesity trials, reports promising VK2735 maintenance data and strengthens its cash position despite widening losses.
4 days ago benzinga.com
Viking Therapeutics Stock Jumps: What's Going On?
Viking Therapeutics Inc (NASDAQ:VKTX) shares are popping Thursday. The obesity drug developer reported third-quarter results that paired a wider-than-expected loss with positive study data and a $960…
4 days ago 247wallst.com
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the…
4 days ago seekingalpha.com
Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The Stock
Viking Therapeutics' maintenance data met upside criteria but failed to excite the market, with shares dropping post-release and dilution ongoing. VKTX is clearly pursuing a standalone strategy,…
4 days ago marketbeat.com
Viking Therapeutics Q3 Earnings Call Highlights
Viking Therapeutics NASDAQ: VKTX reported a wider third-quarter loss as it increased spending on late-stage obesity programs, while advancing phase III studies of both injectable and oral versions of…
5 days ago seekingalpha.com
Viking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcript
Viking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcript
5 days ago prnewswire.com
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Announced for VK2735…
5 days ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 week ago zacks.com
Should You Buy Viking Therapeutics Stock Ahead of Q3 Results?
VKTX is likely to report Q3 results Oct. 28 as investors await updates on VK2735's oral and injectable obesity programs and 2027 data readouts.
1 week ago 247wallst.com
Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction) reports third-quarter results on October 28, 2026. Shares fell 41.
1 week ago zacks.com
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $24.42, signifying a -5.48% move from its prior day's close.
1 week ago zacks.com
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $25.76, denoting a -2.35% move from the preceding trading day.
1 week ago zacks.com
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?
Viking Therapeutics' late-stage obesity drug and promising weight-maintenance data could offer greater upside than Novo Nordisk, despite higher clinical and commercial risks.
1 week ago prnewswire.com
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
Conference Call Scheduled for Wednesday, October 28, at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage…
-
1 week ago benzinga.com
Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106
Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $114 to $106.
1 week ago zacks.com
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
1 week ago zacks.com
Can Viking Therapeutics Carve Out a Place in the Obesity Market?
VKTX advances oral VK2735 into phase III as it explores weight maintenance and faces intensifying obesity drug competition.
1 week ago fool.com
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years
Viking Therapeutics is running Phase 3 studies for subcutaneous VK2735. Positive results could allow the company to carve out a niche in the weight loss market.
-
2 weeks ago benzinga.com
UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94
UBS analyst Joon Lee initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announces Price Target of $94.
-
2 weeks ago benzinga.com
Viking Therapeutics Initiates SUNRISE Phase 3 Clinical Program For Oral VK2735 Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors
VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.The SUNRISE Phase 3 program includes two studies…
2 weeks ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
3 weeks ago benzinga.com
Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85
Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $87 to $85.
-
3 weeks ago benzinga.com
Viking Therapeutics Begins Exploratory Oral Maintenance Dosing Study Of VK2735, Its Dual Agonist Of Glucagon-Like Peptide 1 And Glucose-Dependent Insulinotropic Polypeptide Receptors
VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. The trial announced today is the second in a two-part…
-
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
Benzinga Bulls and Bears: Costco, KB Home, McDonald’s
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
1 month ago benzinga.com
S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today
Stocks pared a sharp morning selloff after sources said US and Iranian negotiators are discussing a phased deal to reopen the Strait of Hormuz.
1 month ago benzinga.com
Crude Oil Rises Over 4%; Darden Earnings Miss Views
U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
1 month ago benzinga.com
Why Is Viking Therapeutics Stock Trading Down Thursday?
A Viking Therapeutics announcement about an equity and debt offering fuels a reaction in the market.
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Profusa (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market session. The company's market cap stands at $1.2 million. GlucoTrack (NASDAQ:GCTK) stock rose 96.55% to…
1 month ago benzinga.com
Stitch Fix Posts Mixed Q4 Results, Joins Viking Therapeutics And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. futures fell as Stitch Fix plunged 18% on weak FY27 guidance; MGM, Viking Therapeutics and other stocks also declined premarket.
-
1 month ago benzinga.com
Viking Therapeutics Prices Concurrent Public Offerings Of 7,857,143 Shares At $35/Shr And $225M Aggregate Principal Amount Of 2.00% Convertible Senior Notes Due 2032
Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of…
1 month ago benzinga.com
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.
1 month ago benzinga.com
Viking Therapeutics Stock Drops In After Hours on Proposed Public Offerings
Viking Therapeutics shares are moving lower in extended trading Wednesday after the company announced a pair of proposed public offerings.
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 million. Greenland Mines…
1 month ago benzinga.com
QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days
Viking Therapeutics stock jumps 40% after VK2735 shows sustained weight loss with less frequent dosing.
-
1 month ago benzinga.com
Viking Therapeutics Announces $200M Common Stock And $200M Convertible Senior Notes Due 2032; Proceeds To Fund VK2735, VK3019 Clinical Development And General Corporate Purposes
Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention…
-
1 month ago benzinga.com
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87
Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $83 to $87.
1 month ago benzinga.com
Jaguar Health, IONQ, Viking Therapeutics, Xanadu Quantum and Grab Holdings: Why These 5 Stocks Are on Investors' Radars Today
JAGX, IONQ, VKTX, XNDU, GRAB were among the stocks seen trending on Tuesday, Sept. 22, 2026.
1 month ago benzinga.com
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
1 month ago benzinga.com
Nasdaq 100 Flirts with Records, Oil Sinks for Fifth Day: Stock Market Today
Nasdaq 100 printed an intraday record on AI enthusiasm while financials slid nearly 2% and crude fell for a fifth straight session.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved…
1 month ago benzinga.com
On Holding, Viking Therapeutics, Shopify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks rose, led by On Holding's 13% surge after strong guidance and a $1B buyback; Viking Therapeutics and others also gained.
1 month ago benzinga.com
Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent Dosing
Viking Therapeutics reports positive VK2735 study results showing effective weight maintenance with monthly and biweekly dosing regimens.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. Greenland Mines (NASDAQ:GRML) shares rose…